35 related articles for article (PubMed ID: 33486440)
1. Glioblastoma patients' survival and its relevant risk factors during the pre-COVID-19 and post-COVID-19 pandemic: real-world cohort study in the USA and China.
Qin L; Li H; Zheng D; Lin S; Ren X
Int J Surg; 2024 May; 110(5):2939-2949. PubMed ID: 38376848
[TBL] [Abstract][Full Text] [Related]
2. The intersection of race and social determinants of health on clinical outcome of glioblastoma patients.
Asfaw ZK; Hernandez-Marquez GC; Naik A; Young T; Vega Perez R; Bickell N; Germano IM
J Neurosurg; 2024 Apr; ():1-10. PubMed ID: 38579343
[TBL] [Abstract][Full Text] [Related]
3. Socioeconomic status and coronary heart disease risk prediction.
Fiscella K; Tancredi D
JAMA; 2008 Dec; 300(22):2666-8. PubMed ID: 19066387
[No Abstract] [Full Text] [Related]
4. Lower middle-income countries: A risk factor for lower survival in glioblastoma? Evidence for health care providers.
Oberndorfer S
Neurooncol Pract; 2023 Aug; 10(4):320-321. PubMed ID: 37457229
[No Abstract] [Full Text] [Related]
5. Sex Disparities in
Smits A; Lysiak M; Magnusson A; Rosell J; Söderkvist P; Malmström A
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33546098
[TBL] [Abstract][Full Text] [Related]
6. Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial.
Reardon DA; Kim TM; Frenel JS; Simonelli M; Lopez J; Subramaniam DS; Siu LL; Wang H; Krishnan S; Stein K; Massard C
Cancer; 2021 May; 127(10):1620-1629. PubMed ID: 33496357
[TBL] [Abstract][Full Text] [Related]
7. The Current State of Adult Glial Tumor Patients' Care in Kazakhstan: Challenges in Diagnosis and Patterns in Survival Outcomes.
Babi A; Menlibayeva K; Bex T; Kuandykova S; Akshulakov S
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979865
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
Weller J; Schäfer N; Schaub C; Potthoff AL; Steinbach JP; Schlegel U; Sabel M; Hau P; Seidel C; Krex D; Goldbrunner R; Pietsch T; Tzaridis T; Zeyen T; Borger V; Güresir E; Vatter H; Herrlinger U; Schneider M
J Neurooncol; 2022 Aug; 159(1):95-101. PubMed ID: 35704157
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?
Gatto L; Di Nunno V; Franceschi E; Tosoni A; Bartolini S; Brandes AA
Drugs; 2022 Apr; 82(5):491-510. PubMed ID: 35397073
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma: Emerging Treatments and Novel Trial Designs.
Di Nunno V; Franceschi E; Tosoni A; Gatto L; Lodi R; Bartolini S; Brandes AA
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359651
[TBL] [Abstract][Full Text] [Related]
11. Racial and socioeconomic disparities in glioblastoma outcomes: A single-center, retrospective cohort study.
Estevez-Ordonez D; Abdelrashid M; Coffee E; Laskay NMB; Atchley TJ; Chkheidze R; Fiveash JB; Markert JM; Lobbous M; Maveal BM; Burt Nabors L
Cancer; 2023 Oct; 129(19):3010-3022. PubMed ID: 37246417
[TBL] [Abstract][Full Text] [Related]
12. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-analysis.
Chen Y; Hu F; Zhou Y; Chen W; Shao H; Zhang Y
Arch Med Res; 2013 May; 44(4):281-90. PubMed ID: 23608672
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
[TBL] [Abstract][Full Text] [Related]
14. Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study.
Tosoni A; Gatto L; Franceschi E; Di Nunno V; Lodi R; Mura A; Di Battista M; Bartolini S; Brandes AA
Eur J Cancer; 2021 Mar; 145():171-178. PubMed ID: 33486440
[TBL] [Abstract][Full Text] [Related]
15. Disparities in health care determine prognosis in newly diagnosed glioblastoma.
Chandra A; Rick JW; Dalle Ore C; Lau D; Nguyen AT; Carrera D; Bonte A; Molinaro AM; Theodosopoulos PV; McDermott MW; Berger MS; Aghi MK
Neurosurg Focus; 2018 Jun; 44(6):E16. PubMed ID: 29852776
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
